Sajjadi Consulting
  • About
  • Services
    • Quality Consulting
    • Professional Development
    • Speaking
  • Events
  • Blog
  • Contact
  • Search
  • Menu Menu
 
You are here: Home1 » Blog2 » Quality Quarterly3 » Developments in Bioassays

Developments in Bioassays

Nancy Sajjadi
Quality Quarterly November 2, 2022

For over 30 years, I have been involved in the quality control of experimental biologics and have witnessed both incredible outcomes and tragic disappointments in addressing many different unmet clinical needs. I recently attended a conference in-person and attended all 16 great talks that catalyzed valuable conversations about developments in bioassays, specifically how to best measure product potency.

Potency is central to a pharmaceutical product’s efficacy and safety profile. Designing and developing bioassays to measure this critical quality attribute for complex biologics is a resource intensive activity.   Adopting a phase appropriate approach allows drug developers to strategically focus time and effort in a stepwise fashion to best satisfy the regulatory requirement for a validated potency assay at licensure.

Relevant biology and statistical analyses are integral to evaluating risks and making smart decisions. My continuing education in this area comes from conferences, courses and ongoing conversations with my clients and colleagues. With in-person conferences on the rebound, I wish to share the following information with you.

Findings from the CASSS Bioassay Conference in Gaithersburg, Maryland (July 19-21, 2022)

Keynote Summary – Dr. Marjorie Shapiro
(Office of Biotechnology Products/OPQ/CDER/FDA)

  1. We’re never done learning about how our products work and the diseases they are used to treat
  2. Accumulation of knowledge is gained by industry and health authorities working together
  3. Continuous learning leads to new and improved bioassays and better products

Conference Take Homes Applicable to Cell and Gene Therapy Products
Regulatory

  1. The distinction between critical raw materials, drug substance and drug product can become blurred in complex C/GT products.The regulatory agencies are asking for more detailed CMC information, at earlier stages in development and with the expectation of “potency testing” on upstream materials that influence the potency of the final product.
  2. Generation and characterization of reference materials must begin early in development and provide enough to evaluate and link pre-clinical and clinical lots using a phase appropriate, matrix-based approach to product potency testing.

Cell lines and Readouts

  1. Primary cells may be more biologically relevant but banked cell lines including highly engineered cell lines (e.g. AAVR over expression, reporter gene) may be required to achieve an assay that is robust enough to be used in QC.
  2. High tech readouts have recently been incorporated into QC testing. Big pharma players have validated FACS and Single Quadrupole Mass Spectrometry as bioassay readouts for lot release testing of an approved COVID vaccine and a gene therapy product in clinical development, respectively.FACS analysis is going to be essential for some cell and gene therapy products.
  3. For CAR-T products, it is unclear whether INF-γ production is a meaningful potency measurement.Off-the-shelf cell lines (e.g. Target Cell Killing (promega.com) are now being used to more directly assess cell killing functionality.For autologous and allogeneic products, a lack of parallelism between reference material and product lots is not uncommon and may reflect the inherent variability of donor starting material and complicate calculation of a RP value.

Design and Data Analysis

  1. In silico tools are being developed and implemented to identify the optimal spacing of dilutions of reference and test samples to cover the expected/desired range for bioassays that yield dose response curves that fit a 4 PL model.  A minimum of 8 points is required with 2 in each asymptote.

This article was originally published as the Sajjadi Consulting Quality Quarterly, sent July 2022. You are invited to subscribe to the quality quarterly.

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
https://sajjadiconsulting.com/wp-content/uploads/2021/09/Nancy-headshot-340x340-1.jpg 340 340 Jill Kurtz https://sajjadiconsulting.com/wp-content/uploads/2021/08/sajjadi-logo-web.png Jill Kurtz2022-11-02 11:05:532022-11-02 11:05:53Developments in Bioassays

Categories

  • Interviews
  • Presentations and Panels
  • Publications
  • Quality Quarterly

Archives

  • March 2023
  • November 2022
  • September 2021
  • June 2021
  • March 2021
  • October 2020
  • October 2019
  • April 2019
  • August 2018
  • March 2005
  • September 2003
  • January 2003
  • December 2000
  • September 2000
  • September 1997
  • July 1997
  • February 1996
  • March 1995
  • June 1994
Sajjadi Consulting Logo

Email:   nancy@sajjadiconsulting.com
Phone: 703-727-9195

LinkedIn logo

Stay in touch by signing up for our email list. Updates will be sent quarterly. Your information will never be shared or sold.

Privacy Policy

Copyright @ 2023 Sajjadi Consulting • All rights reserved.

Co-chair panel Bioassays and statistics FAQs to FACTSTotal Analytical Error (TAE) from Concept to Calculations
Scroll to top

This site uses cookies to improve your browsing experience. The website may not work as expected without them. By continuing to browse this site, you consent to the use of cookies.

Accept settingsHide notification only

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only